124 related articles for article (PubMed ID: 24953334)
1. Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.
Ader I; Delmas C; Skuli N; Bonnet J; Schaeffer P; Bono F; Cohen-Jonathan-Moyal E; Toulas C
Eur J Cancer; 2014 Sep; 50(13):2351-9. PubMed ID: 24953334
[TBL] [Abstract][Full Text] [Related]
2. Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.
Fons P; Gueguen-Dorbes G; Herault JP; Geronimi F; Tuyaret J; Frédérique D; Schaeffer P; Volle-Challier C; Herbert JM; Bono F
J Cell Physiol; 2015 Jan; 230(1):43-51. PubMed ID: 24760775
[TBL] [Abstract][Full Text] [Related]
3. Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells.
Lanvin O; Monferran S; Delmas C; Couderc B; Toulas C; Cohen-Jonathan-Moyal E
Eur J Cancer; 2013 Sep; 49(13):2884-91. PubMed ID: 23747271
[TBL] [Abstract][Full Text] [Related]
4. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
5. Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity.
Hsieh CH; Lee CH; Liang JA; Yu CY; Shyu WC
Oncol Rep; 2010 Dec; 24(6):1629-36. PubMed ID: 21042761
[TBL] [Abstract][Full Text] [Related]
6. FGFR1 Induces Glioblastoma Radioresistance through the PLCγ/Hif1α Pathway.
Gouazé-Andersson V; Delmas C; Taurand M; Martinez-Gala J; Evrard S; Mazoyer S; Toulas C; Cohen-Jonathan-Moyal E
Cancer Res; 2016 May; 76(10):3036-44. PubMed ID: 26896280
[TBL] [Abstract][Full Text] [Related]
7. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance.
Dubois L; Magagnin MG; Cleven AH; Weppler SA; Grenacher B; Landuyt W; Lieuwes N; Lambin P; Gorr TA; Koritzinsky M; Wouters BG
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1219-27. PubMed ID: 19251093
[TBL] [Abstract][Full Text] [Related]
9. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Skuli N; Monferran S; Delmas C; Favre G; Bonnet J; Toulas C; Cohen-Jonathan Moyal E
Cancer Res; 2009 Apr; 69(8):3308-16. PubMed ID: 19351861
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of fibroblast growth factor receptor 1 expression in human glioblastoma cell contributes to the cell growth suppression].
Yamada SM; Yamaguchi F; Morrison RS; Takahashi H; Teramoto A
No To Shinkei; 1998 Dec; 50(12):1101-5. PubMed ID: 9989355
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
Herbert C; Schieborr U; Saxena K; Juraszek J; De Smet F; Alcouffe C; Bianciotto M; Saladino G; Sibrac D; Kudlinzki D; Sreeramulu S; Brown A; Rigon P; Herault JP; Lassalle G; Blundell TL; Rousseau F; Gils A; Schymkowitz J; Tompa P; Herbert JM; Carmeliet P; Gervasio FL; Schwalbe H; Bono F
Cancer Cell; 2013 Apr; 23(4):489-501. PubMed ID: 23597563
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
[TBL] [Abstract][Full Text] [Related]
14. Structural Characterization of the Interaction of the Fibroblast Growth Factor Receptor with a Small Molecule Allosteric Inhibitor.
Kappert F; Sreeramulu S; Jonker HRA; Richter C; Rogov VV; Proschak E; Hargittay B; Saxena K; Schwalbe H
Chemistry; 2018 Jun; 24(31):7861-7865. PubMed ID: 29656465
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
Eshleman JS; Carlson BL; Mladek AC; Kastner BD; Shide KL; Sarkaria JN
Cancer Res; 2002 Dec; 62(24):7291-7. PubMed ID: 12499272
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.
Bono F; De Smet F; Herbert C; De Bock K; Georgiadou M; Fons P; Tjwa M; Alcouffe C; Ny A; Bianciotto M; Jonckx B; Murakami M; Lanahan AA; Michielsen C; Sibrac D; Dol-Gleizes F; Mazzone M; Zacchigna S; Herault JP; Fischer C; Rigon P; Ruiz de Almodovar C; Claes F; Blanc I; Poesen K; Zhang J; Segura I; Gueguen G; Bordes MF; Lambrechts D; Broussy R; van de Wouwer M; Michaux C; Shimada T; Jean I; Blacher S; Noel A; Motte P; Rom E; Rakic JM; Katsuma S; Schaeffer P; Yayon A; Van Schepdael A; Schwalbe H; Gervasio FL; Carmeliet G; Rozensky J; Dewerchin M; Simons M; Christopoulos A; Herbert JM; Carmeliet P
Cancer Cell; 2013 Apr; 23(4):477-88. PubMed ID: 23597562
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor signaling affects vascular outgrowth and is required for the maintenance of blood vessel integrity.
De Smet F; Tembuyser B; Lenard A; Claes F; Zhang J; Michielsen C; Van Schepdael A; Herbert JM; Bono F; Affolter M; Dewerchin M; Carmeliet P
Chem Biol; 2014 Oct; 21(10):1310-1317. PubMed ID: 25200605
[TBL] [Abstract][Full Text] [Related]
18. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
19. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
20. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
